Wearable health technology sits on one of the least intuitive regulatory boundaries a foreign brand entering Japan will encounter. Two products can share nearly identical hardware, a wrist-worn optical heart rate sensor, an accelerometer, a small wireless radio, and land in completely different regulatory categories depending on what the product claims to do. One is a consumer electronics accessory subject to routine product safety rules. The other is a medical device requiring approval from Japan's pharmaceutical regulator before it can be sold at all. Getting this classification wrong before committing to an import structure is one of the most expensive mistakes a wearable brand can make when entering the Japanese market.
The Line Is Drawn by Intended Use, Not by Hardware
Japan's medical device framework sits under the Pharmaceuticals and Medical Devices Act (薬機法, commonly referred to as the PMD Act), administered by the Ministry of Health, Labour and Welfare (厚生労働省, MHLW) together with the Pharmaceuticals and Medical Devices Agency (医薬品医療機器総合機構, PMDA). Whether a wearable falls under this framework is determined primarily by its intended use and the claims made about it, not by its physical form factor. A wrist-worn sensor marketed as providing "general fitness and wellness insight," tracking steps, general activity level, or sleep duration for personal awareness, generally sits outside the PMD Act. A functionally similar device marketed to detect, diagnose, or monitor a specific medical condition, for example a claim to detect irregular heart rhythm consistent with atrial fibrillation, or to measure blood glucose or blood pressure for clinical decision-making, is treated as a medical device regardless of how similar its underlying sensor hardware is to the wellness product next to it on the shelf.
This means the same manufacturer can sell two versions of what is nearly the same physical device into two entirely different regulatory tracks, purely as a function of labeling, marketing language, and the specific function the software presents to the user. Brands frequently underestimate how closely marketing copy, app store descriptions, and even user-facing notification language factor into this determination, not just the formal product specification sheet.
The Non-Medical Track: PSE and Radio Act
A wearable that stays on the general wellness side of the line is not exempt from regulation; it simply falls under a different set of laws than a medical device would. Most wearables incorporate batteries, charging circuitry, and wireless connectivity, which brings them under the Electrical Appliance and Material Safety Act (電気用品安全法, commonly known as PSE) for electrical safety, and the Radio Act (電波法) for any Bluetooth, Wi-Fi, or cellular radio component, which requires the Technical Conformity Mark (技適マーク, often shortened to Giteki) before the device can be legally used or sold in Japan. These two regimes apply to wearable wellness devices the same way they apply to any other piece of connected consumer electronics, and neither requires MHLW or PMDA review.
The Medical Track: PMD Act Classification
Where a wearable's intended use crosses into diagnosis, monitoring, or treatment of a specific medical condition, it is classified under the PMD Act's four-tier, risk-based system. Devices with the lowest risk profile require only a notification filing and do not need pre-market approval from MHLW or PMDA. Moderate-risk devices go through a certification process conducted by a registered third-party certification body rather than a direct government review. The highest-risk categories require full pre-market approval from PMDA, including technical documentation and, depending on the device, clinical evaluation, before the product can be marketed in Japan at all.
Where a specific wearable lands within this four-tier system depends on the clinical function it performs and the risk associated with a false or missed result, and that determination is made by MHLW on the specific device and its labeling. This is a case-by-case regulatory determination, not a general classification a brand can assume by analogy to a similar product already on the market, and it should be confirmed directly with a qualified regulatory consultant or PMDA before a product intended for medical claims is finalized for the Japan launch.
What This Means for the Import Structure
Importer of Record (IOR): if a wearable is confirmed to sit on the general wellness side of the line, Aplash can act as the Importer of Record in the same way it would for any consumer electronics product, purchasing the goods from the overseas manufacturer, filing the import declaration (輸入申告) under the Customs Act (関税法), and re-selling the cleared goods to the Japan buyer once PSE and Radio Act certification are in hand. This is the standard consumer electronics import path and does not involve MHLW or PMDA at any stage.
Attorney for Customs Procedures (ACP, 税関事務管理人): for a non-resident manufacturer that wants to remain the named importer on the declaration rather than transferring title, Aplash can act as the manufacturer's ACP under Article 95 of the Customs Act (関税法), serving as the Japan-resident procedural agent while the manufacturer holds importer status directly. As with any product category, IOR and ACP are separate legal structures with different parties named as importer; the choice is not affected by whether the underlying product is a wellness device or a medical device.
Confirmed medical devices sit on a different track entirely. A wearable classified under the PMD Act requires a Japan marketing authorization holder appropriate to its risk class before it can be sold, and higher-risk classes require a Japan-domiciled entity to hold that authorization. Neither the IOR nor the ACP structure substitutes for this requirement; customs clearance and PMD Act marketing authorization are two separate regulatory tracks, and a device cannot be legally sold in Japan on the strength of a clean customs clearance alone if it also requires PMD Act approval that has not been obtained. Brands confirmed to be in this category should treat the regulatory approval track as the long lead item and sequence the import structure discussion after that path is scoped, not before.
Practical Guidance for Wearable Brands
(a) Classify before you commit to messaging. Decide early whether the product's Japan positioning will make a medical claim, and understand that this decision, not the hardware, drives which regulatory track applies.
(b) Do not assume consistency with other markets. A product treated as a general wellness device in one jurisdiction is not automatically treated the same way in Japan; the classification must be assessed against the PMD Act specifically.
(c) If the product is genuinely borderline, get a determination before launch. Products that measure a physiological signal and present any interpretive output (an alert, a risk flag, a trend claim tied to a named condition) are the most likely to be scrutinized, and an early consultation with a qualified regulatory advisor or PMDA is far cheaper than a post-launch enforcement issue.
(d) Scope PSE and Radio Act regardless of track. Every wearable with a battery and a radio needs these two regimes cleared, independent of whether it also needs PMD Act approval.
(e) Sequence the import structure last. Once classification and the associated compliance track are confirmed, the IOR versus ACP decision follows the same logic as any other consumer electronics or medical device import.
This article is informational only and does not constitute legal, medical device regulatory, or customs advice. Medical device classification under the Pharmaceuticals and Medical Devices Act is a case-by-case determination made by Japanese regulatory authorities; consult a qualified regulatory affairs specialist and, where warranted, the Pharmaceuticals and Medical Devices Agency directly before finalizing a Japan launch for any product with a health-related claim. Last updated: July 2026. Aplash is a regulatory strategy and market entry firm.